Potassium Channel Modulator Crystalline Forms for SK2 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with potassium channel dysfunction lack effective modulators, particularly for small conductance calcium-activated potassium subtype 2 (SK2) channels, which are crucial for neuronal excitability and smooth muscle regulation.
Innovation Solution
Development of amorphous and crystalline forms of Compound 1, a small molecule modulator, which includes specific pharmaceutical compositions and processes for treating diseases related to potassium channel activity, characterized by XRPD, TGA, and DSC patterns, and used to modulate SK2 channels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing potassium channel modulators are used, then some therapeutic effects are achieved, but effective treatment for SK2 channel-related diseases is insufficient
Solution Approach 1:
The patent modifies the chemical structure of Compound 1 by changing physical and chemical parameters (crystalline form, polymorph structure) to achieve enhanced SK2 channel modulation. Different crystalline forms (Form A, B, C, D, E, F) were generated through controlled crystallization processes, each with distinct XRPD patterns and therapeutic properties, allowing optimization for specific disease indications.
Solution Approach 2:
The patent utilizes phase transitions from amorphous to crystalline forms of Compound 1 to improve therapeutic effectiveness. The amorphous form was converted to multiple crystalline forms through controlled crystallization processes, resulting in stable solid forms with enhanced bioavailability and efficacy for treating SK2 channel-related diseases.
2Reliability
If multiple crystalline forms of Compound 1 are developed, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the crystalline forms of Compound 1 into distinct types (Form A, B, C, D, E, F) with different XRPD patterns and properties. Each form can be manufactured through specific crystallization conditions, allowing selective production based on therapeutic requirements while maintaining processability through standardized purification techniques.
Solution Approach 2:
The patent controls crystallization parameters (temperature, solvent composition, pH, agitation rate) to generate different crystalline forms from the same amorphous precursor. By adjusting these parameters, multiple forms with optimized properties can be produced using a single synthetic pathway, reducing overall manufacturing complexity.
3Adaptability or versatility
If amorphous and crystalline forms are provided, then treatment versatility is enhanced, but characterization requirements increase
Solution Approach 1:
The patent utilizes distinct XRPD patterns (diffraction peak positions and intensities) as characteristic signatures to identify and differentiate between amorphous and crystalline forms, as well as between different crystalline forms. These pattern recognition methods provide reliable characterization without complex analytical procedures.
Solution Approach 2:
The patent replaces complex multi-parameter characterization methods with simpler techniques focused on XRPD pattern analysis, TGA thermal profiles, and DSC melting points. These methods provide sufficient differentiation between forms using straightforward measurements rather than complex structural analysis.
Data Source
AI summary
Provided herein are crystalline and amorphous forms of a compound having structural formula (1). Also provided are pharmaceutical compositions comprising the crystalline and amorphous forms, methods for their manufacture, and uses thereof for treating a variety of diseases, disorders or conditions, associated with potassium channels.